1-4 of 4
E. John Wherry
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

FDG PET/CT Imaging 1 Week after a Single Dose of Pembrolizumab Predicts Treatment Response in Patients with Advanced Melanoma

Thomas M. Anderson, Bryan H. Chang, Alexander C. Huang, Xiaowei Xu, Daniel Yoon, Catherine G. Shang, Rosemarie Mick, Erin Schubert, Suzanne McGettigan, Kristin Kreider, Wei Xu, E. John Wherry, Lynn M. Schuchter, Ravi K. Amaravadi, Tara C. Mitchell, Michael D. Farwell
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (9): 1758–1767.
https://doi.org/10.1158/1078-0432.CCR-23-2390
Published: 01 May 2024
View article titled, FDG PET/CT Imaging 1 Week after a Single Dose of Pembrolizumab Predicts Treatment Response in Patients with Advanced Melanoma
Open the PDF for FDG PET/CT Imaging 1 Week after a Single Dose of Pembrolizumab Predicts Treatment Response in Patients with Advanced Melanoma in another window
Includes: Supplementary data
Journal Articles

Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer

Katelyn T. Byrne, Courtney B. Betts, Rosemarie Mick, Shamilene Sivagnanam, David L. Bajor, Daniel A. Laheru, E. Gabriela Chiorean, Mark H. O'Hara, Shannon M. Liudahl, Craig Newcomb, Cécile Alanio, Ana P. Ferreira, Byung S. Park, Takuya Ohtani, Austin P. Huffman, Sara A. Väyrynen, Andressa Dias Costa, Judith C. Kaiser, Andreanne M. Lacroix, Colleen Redlinger, Martin Stern, Jonathan A. Nowak, E. John Wherry, Martin A. Cheever, Brian M. Wolpin, Emma E. Furth, Elizabeth M. Jaffee, Lisa M. Coussens, Robert H. Vonderheide
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (16): 4574–4586.
https://doi.org/10.1158/1078-0432.CCR-21-1047
Published: 15 August 2021
View article titled, Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer
Open the PDF for Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer in another window
Includes: Supplementary data
Journal Articles

How Did We Get a COVID-19 Vaccine in Less Than 1 Year?

E. John Wherry, Elizabeth M. Jaffee, Nicholas Warren, Gypsyamber D'Souza, Antoni Ribas
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (8): 2136–2138.
https://doi.org/10.1158/1078-0432.CCR-21-0079
Published: 15 April 2021
View article titled, How Did We Get a COVID-19 Vaccine in Less Than 1 Year?
Open the PDF for How Did We Get a COVID-19 Vaccine in Less Than 1 Year? in another window
Journal Articles

Multifactorial T-cell Hypofunction That Is Reversible Can Limit the Efficacy of Chimeric Antigen Receptor–Transduced Human T cells in Solid Tumors

Edmund K. Moon, Liang-Chuan Wang, Douglas V. Dolfi, Caleph B. Wilson, Raghuveer Ranganathan, Jing Sun, Veena Kapoor, John Scholler, Ellen Puré, Michael C. Milone, Carl H. June, James L. Riley, E. John Wherry, Steven M. Albelda
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (16): 4262–4273.
https://doi.org/10.1158/1078-0432.CCR-13-2627
Published: 13 August 2014
View article titled, Multifactorial T-cell Hypofunction That Is Reversible Can Limit the Efficacy of Chimeric Antigen Receptor–Transduced Human T cells in Solid Tumors
Open the PDF for Multifactorial T-cell Hypofunction That Is Reversible Can Limit the Efficacy of Chimeric Antigen Receptor–Transduced Human T cells in Solid Tumors in another window
Includes: Supplementary data